Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Xiyang Liu, Liqing Kang, Hongfei Gu, Wei Zhang, Hongjia Zhu, Xue Lu, Huan Zhou, Xingyue Wang, Nan Xu, Xiaoyan Lou, Minghao Li, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Lei Yu, Peihua Lu

Blood (2025) 146 (Supplement 1): 3713.

https://doi.org/10.1182/blood-2025-3713

Published: 2025

Journal Articles

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

Xiyang Liu, Hongjia Zhu, Wei Zhang, Liqing Kang, Hongfei Gu, Xue Lu, Huan Zhou, Xingyue Wang, Nan Xu, Xiaoyan Lou, Minghao Li, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Peihua Lu, Lei Yu

Blood (2025) 146 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2025-2382

Published: 2025

Journal Articles

A novel loop-structured CD19/CD22 dual-targeting CAR-T therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Wei Zhang, Nan Xu, Hongfei Gu, Xiyang Liu, Liqing Kang, Hongjia Zhu, Xingyue Wang, Xue Lu, Huan Zhou, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Xiaoyan Lou, Minghao Li, Lei Yu, Peihua Lu

Blood (2025) 146 (Supplement 1): 4152.

https://doi.org/10.1182/blood-2025-4152

Published: 2025

Journal Articles

Multitarget kinase inhibitor olverembatinib is active and synergizes with BTK inhibitor acalabrutinib in preclinical models of Mantle Cell Lymphoma

Bo Peng, Zhiyan Liang, Yan Xiong, Bingxing Wu, Yanqiu Ji, Zhou Yu, Dajun Yang, Yifan Zhai

Blood (2025) 146 (Supplement 1): 6814.

https://doi.org/10.1182/blood-2025-6814

Published: 2025

Journal Articles

Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM)

Yan Yin, Zhiyan Liang, Baisong Li, Zhou Yu, Daojie Liu, Shujie He, Dajun Yang, Yifan Zhai

Blood (2025) 146 (Supplement 1): 1528.

https://doi.org/10.1182/blood-2025-1528

Published: 2025

Journal Articles

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Blood (2025) 146 (Supplement 1): 927.

https://doi.org/10.1182/blood-2025-927

Published: 2025

Journal Articles

APG-2449, a Novel Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Antileukemic Activity and Enhances Lisaftoclax (APG-2575)-Induced Apoptosis in Acute Myeloid Leukemia (AML)

Zhou Yu, Zhiyan Liang, Xinyi Yao, Yanqiu Ji, Dajun Yang, Yifan Zhai

Blood (2024) 144 (Supplement 1): 4150.

https://doi.org/10.1182/blood-2024-202693

Published: 2024

Journal Articles

Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells

Blood (2024) 144 (Supplement 1): 4794.

https://doi.org/10.1182/blood-2024-206406

Published: 2024

Journal Articles

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Qian Cheng, JingWen Tan, Rui Liu, Liqing Kang, Hongjia Zhu, Yi Zhang, Erhua Wang, Ying Li, Jian Zhang, Han Xiao, Rong He, Xiaoyan Lou, Nan Xu, Wei Wang, Zhou Yu, Minghao Li, Hongfei Gu, Lei Yu, Xin Li

Blood (2024) 144 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2024-200516

Published: 2024

Journal Articles

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Blood (2023) 142 (Supplement 1): 889.

https://doi.org/10.1182/blood-2023-172615

Published: 2023

Journal Articles

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

Liqing Kang, Shengli Xue, Xiaowen Tang, Xiaoyan Lou, Chongsheng Qian, Wenjie Gong, Mingzhu Xu, Haixia Zhou, Zhen Yao, Wei Wang, Minghao Li, Nan Xu, Zhou Yu, Suning Chen, Huiying Qiu, Haiping Dai, Yang Xu, Depei Wu, Lei Yu

Blood (2023) 142 (Supplement 1): 3477.

https://doi.org/10.1182/blood-2023-181552

Published: 2023

Journal Articles

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Liqing Kang, Xiaowen Tang, Nan Xu, Minghao Li, Jingwen Tan, Wei Qi, Zhou Yu, Xiaoyan Lou, Shengli Xue, Xin Li, MD, Jian Zhang, MD, Jia Chen, MD, Zhenkun Wang, PhD, Caixia Li, Fu Cheng Cheng, MD PhD, Depei Wu, MD PhD, Lei Yu, MD PhD

Blood (2019) 134 (Supplement_1): 2621.

https://doi.org/10.1182/blood-2019-132067

Published: 2019

Journal Articles

The Clinical Characteristics, Genetic Alterations and Prognostic Significance of Acute Myeloid Leukemia (AML) with Trisomy 8

Bolanle Gbadamosi, MD, Daniel E Ezekwudo, MD PhD, Foluso Ogunleye, MD, Sanjog Bastola, MD, Mary Coffey, PhD, Zhou Yu, MD PhD, Hong Ye, PhD, Michael Stender, MD, Dana Zakalik, MD, Mark Micale, PhD, Ishmael Jaiyesimi, DO, MS

Blood (2017) 130 (Supplement 1): 5101.

https://doi.org/10.1182/blood.V130.Suppl_1.5101.5101

Published: 2017

Journal Articles

Does Normal Reticulocyte Hemoglobin Rule out Iron Deficiency As a Cause of Normocytic Normochromic Anemia?

Zhou Yu, MD PhD, Leann Michelle Blankenship, MD, Mohammed Ibrahim, MD, Bolanle Gbadamosi, MD, Michael Stender, MD, Joseph Anderson, MD, Ishmael Jaiyesimi, DO, James Huang, MD

Blood (2016) 128 (22): 4826.

https://doi.org/10.1182/blood.V128.22.4826.4826

Published: 2016

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

A novel loop-structured CD19/CD22 dual-targeting CAR-T therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Multitarget kinase inhibitor olverembatinib is active and synergizes with BTK inhibitor acalabrutinib in preclinical models of Mantle Cell Lymphoma

Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM)

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

APG-2449, a Novel Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Antileukemic Activity and Enhances Lisaftoclax (APG-2575)-Induced Apoptosis in Acute Myeloid Leukemia (AML)

Target Antigen-Expressing T Cells Facilitate CAR-T Cell Eradication of Residual CD19+ B Malignant Cells

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Efficacy and Safety of Interleukin-6-Knockdown CD19-Targeted CAR T Cells(ssCART-19) for Relapsed/Refractory B-ALL

Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

The Clinical Characteristics, Genetic Alterations and Prognostic Significance of Acute Myeloid Leukemia (AML) with Trisomy 8

Does Normal Reticulocyte Hemoglobin Rule out Iron Deficiency As a Cause of Normocytic Normochromic Anemia?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only